Evaluation of anti-parasitic activities of new quinolones containing nitrofuran moiety against Toxoplasma gondii
Copyright © 2022 Elsevier Inc. All rights reserved..
Toxoplasmosis is a disease with a worldwide prevalence that is caused by Toxoplasma gondii. Pyrimethamine and sulfadiazine are two pharmacological agents commonly used to treat of this infection. However, they are accompanied by some side effects. Therefore, the identifying of new drugs with low toxocytosis seems to be a matter of vital importance. Quinolones are DNA replication inhibitors, exerting inhibitory effects against many pathogens, including bacteria, mycoplasma, and protozoa. Given the importance of quinolones and their efficacy, the present in vitro study was conducted to investigate the antiparasitic activities of new quinolones (NFQ-2, NFQ-5, and NFQ-6) containing nitrofuran moiety against T. gondii. To this end, Vero cells were incubated with various concentrations of new quinolones and pyrimethamine (positive control) to determine their viability. Subsequently, they were infected with T. gondii (RH strain) and then subjected to drug treatment. The obtained IC50 values were 3.60, 4.84, 5.59, 3.44 and 2.75 μg/mL for NFQ-2, NFQ-5, NFQ-6, ciprofloxacin and pyrimethamine, respectively. The CC50 values for the NFQ-2, NFQ-5, and NFQ-6 were 25.20, 29.89, and 28.43 μg/mL, indicating the selectivity indexes more than 5 for these compounds. The anti-Toxoplasma efficiency was determined by evaluating infection index, number and size of plaques, and T. gondii intracellular proliferation. As the results indicated, the administration of new quinolone derivatives resulted in the reduction of intracellular proliferation, infection index, and the number and size of plaques in comparison to uninfected treated cells (P < 0.05). The results were indicative of a considerable synergetic effect when each of the derivatives was used in combination with pyrimethamine, compared to when used alone. Based on our results, the nitrofuran-derived quinolones can be considered as new leads for the design of new anti-Toxoplasma agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:240 |
|---|---|
| Enthalten in: |
Experimental parasitology - 240(2022) vom: 20. Sept., Seite 108344 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sadeghi, Mitra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5-Nitrofuran |
|---|
| Anmerkungen: |
Date Completed 23.08.2022 Date Revised 23.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.exppara.2022.108344 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344506568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344506568 | ||
| 003 | DE-627 | ||
| 005 | 20231226022928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.exppara.2022.108344 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344506568 | ||
| 035 | |a (NLM)35931176 | ||
| 035 | |a (PII)S0014-4894(22)00138-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sadeghi, Mitra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of anti-parasitic activities of new quinolones containing nitrofuran moiety against Toxoplasma gondii |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2022 | ||
| 500 | |a Date Revised 23.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Toxoplasmosis is a disease with a worldwide prevalence that is caused by Toxoplasma gondii. Pyrimethamine and sulfadiazine are two pharmacological agents commonly used to treat of this infection. However, they are accompanied by some side effects. Therefore, the identifying of new drugs with low toxocytosis seems to be a matter of vital importance. Quinolones are DNA replication inhibitors, exerting inhibitory effects against many pathogens, including bacteria, mycoplasma, and protozoa. Given the importance of quinolones and their efficacy, the present in vitro study was conducted to investigate the antiparasitic activities of new quinolones (NFQ-2, NFQ-5, and NFQ-6) containing nitrofuran moiety against T. gondii. To this end, Vero cells were incubated with various concentrations of new quinolones and pyrimethamine (positive control) to determine their viability. Subsequently, they were infected with T. gondii (RH strain) and then subjected to drug treatment. The obtained IC50 values were 3.60, 4.84, 5.59, 3.44 and 2.75 μg/mL for NFQ-2, NFQ-5, NFQ-6, ciprofloxacin and pyrimethamine, respectively. The CC50 values for the NFQ-2, NFQ-5, and NFQ-6 were 25.20, 29.89, and 28.43 μg/mL, indicating the selectivity indexes more than 5 for these compounds. The anti-Toxoplasma efficiency was determined by evaluating infection index, number and size of plaques, and T. gondii intracellular proliferation. As the results indicated, the administration of new quinolone derivatives resulted in the reduction of intracellular proliferation, infection index, and the number and size of plaques in comparison to uninfected treated cells (P < 0.05). The results were indicative of a considerable synergetic effect when each of the derivatives was used in combination with pyrimethamine, compared to when used alone. Based on our results, the nitrofuran-derived quinolones can be considered as new leads for the design of new anti-Toxoplasma agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 5-Nitrofuran | |
| 650 | 4 | |a Anti-parasitic activity | |
| 650 | 4 | |a Quinolones | |
| 650 | 4 | |a Toxoplasmosis | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Antiprotozoal Agents |2 NLM | |
| 650 | 7 | |a Nitrofurans |2 NLM | |
| 650 | 7 | |a Quinolones |2 NLM | |
| 650 | 7 | |a Pyrimethamine |2 NLM | |
| 650 | 7 | |a Z3614QOX8W |2 NLM | |
| 700 | 1 | |a Sarvi, Shahabeddin |e verfasserin |4 aut | |
| 700 | 1 | |a Emami, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Khalilian, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Seyed Abdollah |e verfasserin |4 aut | |
| 700 | 1 | |a Montazeri, Mahboobeh |e verfasserin |4 aut | |
| 700 | 1 | |a Shahdin, Shayesteh |e verfasserin |4 aut | |
| 700 | 1 | |a Nayeri, Tooran |e verfasserin |4 aut | |
| 700 | 1 | |a Daryani, Ahmad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental parasitology |d 1953 |g 240(2022) vom: 20. Sept., Seite 108344 |w (DE-627)NLM000040436 |x 1090-2449 |7 nnns |
| 773 | 1 | 8 | |g volume:240 |g year:2022 |g day:20 |g month:09 |g pages:108344 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.exppara.2022.108344 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 240 |j 2022 |b 20 |c 09 |h 108344 | ||